Skip to main content

Kalaris Therapeutics, Inc.

KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001754068

No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Kalaris Therapeutics, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of KLRS: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders8786−1
Shares37.2M37.6M+408.8K (+1.1%)
Value$293.7M$193.1M−$100.6M (−34.3%)

New holders (15)

Institutions that held Kalaris Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to KLRS in Q4 2022
InstitutionSharesValue% of portfolio
Citadel Advisors LLC77,783$399.0K0.00%
Squarepoint Ops LLC72,669$372.8K0.00%
Trexquant Investment LP67,984$348.8K0.01%
HRT Financial LP48,028$246.0K0.00%
SVB Financial Group43,019$220.7K0.60%
Jump Financial, LLC37,356$191.6K0.01%
Balyasny Asset Management LLC33,894$173.9K0.00%
Millennium Management LLC26,878$138.0K0.00%
Virtus ETF Advisers LLC20,906$107.2K0.06%
Principal Financial Group Inc17,262$88.6K0.00%
Manufacturers Life Insurance Company, The13,697$70.3K0.00%
Aquatic Capital Management LLC12,500$64.0K0.00%
Ergoteles LLC11,764$60.3K0.00%
Point72 Middle East FZE4,988$25.6K0.00%
Lazard Asset Management LLC1,874$9.00K0.00%

Sold out (16)

Institutions that held Kalaris Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.